Search

Zentalis Pharmaceuticals Inc

Lezárt

3.87 -0.26

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

3.82

Maximum

3.91

Fő mutatók

By Trading Economics

Bevétel

-42M

-78M

Egy részvényre jutó nyereség

-0.59

Munkavállalók

106

EBITDA

-42M

-77M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+126.99% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 6.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

25M

356M

Előző nyitás

4.13

Előző zárás

3.87

Zentalis Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 27. 23:56 UTC

Robert Half Inc. shares are roughly flat in after-market hours amid mixed market sentiment and ongoing inflation concerns influencing Federal Reserve rate hike expectations.

2026. aug. 27. 23:56 UTC

Bright Horizons Family Solutions shares declined in after-market trading, despite remaining above their 20-day moving average amid mixed market sentiment and inflation concerns.

2026. aug. 27. 23:56 UTC

Correlated Moves

Rockwell Automation Inc shares are lower in after-market trading, reflecting broader market sentiment amid inflation data and expectations for a potential Federal Reserve rate hike.

2026. aug. 27. 23:56 UTC

Savara Inc shares are higher in after-market trading, despite no specific news. Broader market sentiment remains mixed amid ongoing inflation concerns and upcoming Fed guidance.

2026. aug. 27. 23:56 UTC

Entravision Communications Corp. shares remained roughly flat in after-market hours, with no specific news identified amid mixed market sentiment and inflation concerns.

2026. aug. 27. 23:56 UTC

Tennant Co. shares are lower in after-market trading, reflecting mixed market sentiment and ongoing inflation concerns influencing investor expectations for a Federal Reserve rate hike.

2026. aug. 27. 23:56 UTC

News Corp shares declined in after-market trading following Thursday's close, amid mixed market sentiment and inflation concerns ahead of Federal Reserve comments.

2026. aug. 27. 23:56 UTC

Coursera Inc. shares are lower in after-market hours, with no specific news identified. Market sentiment is mixed amid inflation concerns and Fed policy anticipation.

2026. aug. 27. 23:56 UTC

WEX Inc shares are lower in after-market hours with no specific news identified. Broader market sentiment is mixed amid ongoing inflation concerns.

2026. aug. 27. 23:56 UTC

Omnicell Inc. shares are higher in after-market trading, despite lacking specific company news. Recent economic data continues to influence market sentiment.

2026. aug. 27. 23:56 UTC

CVS Health shares are higher in after-market trading, recovering from an earlier dip. Market sentiment remains mixed amid ongoing inflation pressures in the U.S.

2026. aug. 27. 23:56 UTC

Shares of Martin Marietta Materials Inc. moved higher in after-market trading, maintaining gains since Thursday's close, though still below its 20-day moving average.

2026. aug. 27. 23:56 UTC

Correlated Moves
News

Royal Gold shares are higher in after-market trading following CEO Bill Heissenbuttel's upcoming presentation at the Jefferies Global Industrials Conference on September 10.

2026. aug. 27. 23:56 UTC

Correlated Moves
News

Diamondback Energy has risen in after-market hours following its joint venture for the Solitude Pipeline System, with analysts estimating a fair value of $232.17.

2026. aug. 27. 23:56 UTC

ETF Constituents

iShares MSCI Brazil ETF declines in after-market trading due to losses from key holdings VALE and PBR.A, despite mixed global equity sentiment.

2026. aug. 27. 23:56 UTC

Correlated Moves

Digital Realty Trust shares are lower in after-market trading, reflecting broader sector declines amid ongoing inflation concerns and anticipation of guidance from the Fed.

2026. aug. 27. 23:56 UTC

Coca-Cola Consolidated Inc shares are lower in after-market trading. No specific company news was identified to explain the decline amid mixed market sentiment.

2026. aug. 27. 23:56 UTC

EUR/DKK trading roughly flat as mixed sentiment persists amid ongoing inflation concerns and expectations for a Federal Reserve rate hike ahead of Jackson Hole.

2026. aug. 27. 23:52 UTC

Mexican Consumer Confidence Index Set for Release Amid Mixed Market Sentiment and Ongoing Economic Challenges.

2026. aug. 27. 23:52 UTC

Japan's July unemployment rate drops to 2.4%, beating forecasts and signaling economic resilience despite inflation concerns.

2026. aug. 27. 23:52 UTC

ADP Employment Change Report on September 2, 2026, Expected to Reveal Slowing Job Growth Amid Economic Uncertainty.

2026. aug. 27. 23:52 UTC

Anticipation Builds for Fed Chair Kevin Warsh's Keynote at Jackson Hole Symposium Amid Inflation Concerns and Interest Rate Speculations.

2026. aug. 27. 23:51 UTC

U-Haul Holding Co shares are lower in after-market hours, continuing a seven-session decline amid broader market dynamics and recent economic data on the labor market.

2026. aug. 27. 23:51 UTC

Transcat Inc shares are trading lower in after-market hours, with no specific news identified to explain the decline. The stock remains below its 20-day moving average.

2026. aug. 27. 23:51 UTC

Insperity Inc. shares are lower in after-market trading, reflecting stability amid broader market dynamics with no specific news identified.

2026. aug. 27. 23:51 UTC

Evertec Inc shares are lower in after-market hours, reflecting broader market trends. Rising Treasury yields and economic data contribute to the downward pressure.

2026. aug. 27. 23:51 UTC

Science Applications International Corp. shares are higher in after-market hours, continuing an upward trend since Thursday's close and remaining above the 20-day moving average.

2026. aug. 27. 23:51 UTC

Trinity Industries Inc shares are lower in after-market hours, continuing a trend of declines over the past three sessions without any specific news identified.

2026. aug. 27. 23:51 UTC

Yelp Inc shares are lower in after-market hours amid broader market declines. Economic data and geopolitical tensions contribute to negative sentiment in equity markets.

2026. aug. 27. 23:51 UTC

SLM Corp shares are lower in after-market trading amid a broader market decline and rising Treasury yields, reflecting cautious investor sentiment.

Társak összehasonlítása

Árváltozás

Zentalis Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

126.99% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 8.83 USD  126.99%

Magas 11 USD

Alacsony 5 USD

6 Wall Street elemző 12 hónapos célárain alapulva a(z)Zentalis Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

6 ratings

5

Vétel

1

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat